Session Detail


Session Title: Early Phase Clinical Trials of Novel Targeted Agents
Session Type: Clinical Trials Minisymposium
Session Start/End Time: Monday, Apr 07, 2014, 3:00 PM - 5:00 PM
Location: Room 29, San Diego Convention Center
CME: CME-Designated
CME/CE Hours: 2
Presentations:
Chairperson
Monday, Apr 07, 2014, 3:00 PM - 5:00 PM
S. Percy Ivy. NCI-DCTD, Rockville, MD
Chairperson
Monday, Apr 07, 2014, 3:00 PM - 5:00 PM
Lillian L. Siu. Univ. Health Network Princess Margaret Hospital, Toronto, ON, Canada
Introduction
Monday, Apr 07, 2014, 3:00 PM - 3:05 PM
CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial
Monday, Apr 07, 2014, 3:05 PM - 3:20 PM
Gerald S. Falchook1, David S. Hong1, Hesham M. Amin2, Siqing Fu1, Sarina Anne Piha-Paul1, Filip Janku1, J. Gabrielle Granda2, HongXia Zheng3, Manfred B. Klevesath4, Karola Köhler5, Friedhelm Bladt4, Andreas Johne6, Razelle Kurzrock7. 1MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Houston, TX; 2MD Anderson Cancer Center, Department of Hematopathology, Houston, TX; 3EMD Serono, Global Research and Early Development, Boston, MA; 4Merck KGaA, Translational Innovation Platform Oncology, Global Research & Development, Darmstadt, Germany; 5Premier Research Germany Ltd, Biostatistics, Darmstadt, Germany; 6Merck KGaA, Clinical Pharmacology, Darmstadt, Germany; 7University of California San Diego Moores Cancer Center, San Diego, CA
CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer
Monday, Apr 07, 2014, 3:20 PM - 3:35 PM
Jimmy Hwang1, Roger Cohen2, Kimberly Perez3, Howard Safran3, Aiwu Ruth He4, Jennifer Giles5, Tianle Hu5, Brian Moser5, Patricia Kellie Turner5, Richard A. Walgren5, Elizabeth Plimack6. 1Levine Cancer Institute, Charlotte, NC; 2Abramson Cancer Center, Philadelphia, PA; 3Lifespan, Providence, RI; 4Georgetown University Medical Center, Washington, DC; 5Eli Lilly and Company, Indianapolis, IN; 6Fox Chase Cancer Center, Philadelphia, PA
CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)
Monday, Apr 07, 2014, 3:35 PM - 3:50 PM
Martin J. Edelman1, Xiaofei Wang2, Lydia Hodgson2, Richard T. Cheney3, Maria Baggstrom4, Thomas Sachdev5, Ajeet Gajra6, Erin Bertino7, Karen Reckamp8, Julian Molina9, Joan Schiller10, Kisha Mitchell-Richards11, Paula Friedman12, Jon Ritter13, Everett Vokes12, Alliance for Clinical Trials in Oncology. 1Univ. of New Mexico Cancer Center, Albuquerque, NM; 2Duke University, Durham, NC; 3Roswell Park Cancer Institute, Buffalo, NY; 4Washington University, St. Louis, MO; 5Illinois Cancer Care, Peoria, IL; 6Upstate Medical University, Syracuse, NY; 7Ohio State University Medical Center, Columbus, OH; 8City of Hope National Medical Center, Duarte, CA; 9Mayo Clinic, Rochester, MN; 10University of Texas Southwestern, Dallas, TX; 11Yale University, New Haven, CT; 12University of Chicago, Chicago, IL; 13University of Minnesota, Minneapolis, MN
CT239: ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
Monday, Apr 07, 2014, 3:50 PM - 4:05 PM
Dana E. Rathkopf1, Emmanuel S. Antonarakis2, Neal D. Shore3, Ronald Tutrone4, Joshi J. Alumkal5, Charles J. Ryan6, Mansoor N. Saleh7, Ralph J. Hauke8, Rajesh Bandekar9, Edna Chow Maneval10, Carla de Boer11, Mary Todd12, Margaret K. Yu13, Howard I. Scher1. 1Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY; 2Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; 3Carolina Urologic Research Center, Myrtle Beach, SC; 4Chesapeake Urologic Research Associates, Baltimore, MD; 5Oregon Health and Science University, Knight Cancer Institute, Portland, OR; 6USCF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 7Georgia Cancer Specialists PC, Sandy Springs, GA; 8Nebraska Cancer Specialists, Omaha, NE; 9Janssen Research & Development, Philadelphia, PA; 10Aragon Pharmaceuticals, San Diego, CA; 11Janssen Biologics, B. V., Leiden, Netherlands; 12Janssen Global Services, Raritan, NJ; 13Janssen Research & Development, Los Angeles, CA
CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients
Monday, Apr 07, 2014, 4:05 PM - 4:20 PM
Charles Ferté, Christophe Massard, Ecaterina Ileana, Antoine Hollebecque, Ludovic Lacroix, Samy Ammari, Maud Ngo-Camus, Rastislav Bahleda, Anas Gazzah, Andrea Varga, Sophie Postel-Vinay, Yohann Loriot, Nathalie Auger, Valerie Koubi-Pick, Bastien Job, Thierry De Baere, Frederic Deschamps, Philippe Vielh, Vladimir Lazar, Marie-Cécile Le Deley, Catherine Richon, Vincent Ribrag, Eric Deutsch, Eric Angevin, Gilles Vassal, Alexander Eggermont, Fabrice André, Jean-Charles Soria. Gustave Roussy, Villejuif, France
CT241: Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology
Monday, Apr 07, 2014, 4:20 PM - 4:35 PM
Arlene O. Siefker-Radtke, Woonyoung Choi, John Melquist, Yu Shen, Ashish Kamat, Surena Matin, Randall Millikan, Colin P. Dinney, Bodgan A. Czernial, David J. McConkey. UT M.D. Anderson Cancer Ctr., Houston, TX, Essentia Health Cancer Center Duluth, Duluth, MN
Discussion
Monday, Apr 07, 2014, 4:35 PM - 5:00 PM